AKT1 and cancer: Besides, in SCC cells, TGF-β can activate the AKT pathway, followed by overexpression of SOX2 and ABCG2, which are characteristic of cancer stem cells, indicating the ability to induce cancer cell dedifferentiation that corresponds to cisplatin resistance [126].